Home > Back to Publisher > Report Information

H4-13, Market Access, Pricing, and Reimbursement News in the Third Quarter of 2009

Decision Resources
October 28, 2009
40 Pages - SKU: DECR2497084

Abstract Table of Contents Related Reports

Countries covered: Japan, France, Germany

Introduction:

The third quarter of 2009 saw a heated debate in the United States over healthcare reform, the publication of a report on a European investigation of the pharmaceutical industry, the election of new governments in Japan and Germany, and new initiatives by governments in other countries to control their national pharmaceutical spending. Faced with declining revenues and increasing expenditures, healthcare payers in all markets are exerting increasing pressure on the pharmaceutical industry to cut costs and deliver genuine innovation.

Questions Answered in This Report:

In the United States, the Democrats are committed to passing healthcare reform legislation by the end of the year. What difficulties have lawmakers encountered in drafting legislation? What are the recent trends in health insurance coverage in the United States? What deal has the U.S. government struck with the pharmaceutical industry?
The French government is looking to cut $2 billion from the national healthcare budget in 2010. How much does the government hope to save by cutting prices, reducing the reimbursement rate of certain drugs, and stimulating greater use of generics? What impact are new voluntary physician contracts likely to have on the French pharmaceutical market?
Spending on prescription drugs by the German statutory health insurance system grew by 5.3% in 2008. How did spending and pricing trends compare for generic and branded drugs? What changes would some health insurance funds like the government to make to controls on pharmaceutical coverage? What new restriction has the government introduced on coverage for certain cancers?
The economic downturn is beginning to have an impact on the U.K. healthcare system. What is the effect on pharmaceutical budgets? How have recent price cuts and exchange rate movements altered parallel trade patterns and contributed to shortages of certain drugs?
The Japanese pricing and reimbursement environment faces the prospect of significant changes in the coming years. How is the new government likely to respond to industry proposals for a price maintenance system? How will generics feature in future government healthcare policy? What are the implications of a recently confirmed restriction on access to drugs not yet approved in Japan?

Scope:

Issues affecting the pharmaceutical industry in the United States: healthcare reform; health insurance trends; drug benefit trends; managed care executives' views on comparative effectiveness research; regulatory pathway for biosimilars.
Issues affecting the pharmaceutical industry in Europe: market trends; generic drug use; proposed prescribing and reimbursement restrictions; shifting patterns of parallel trade; impact of the economic downturn on the pharmaceutical market; access to medicines.
Issues affecting the pharmaceutical industry in Japan: prospects for the introduction of a price maintenance system; government policy on generics; reimbursement of drugs not yet approved in Japan.

Please note, the PDF e-mail from publisher version of this report is for a global site license.

Executive Summary: Strategic Considerations; Stakeholder Implications
Overview
United States: Healthcare Reform; Health Insurance Trends; Drug Benefi t Trends; Comparative Effectiveness Research; Regulatory Pathway for Biosimilars
European Union: Publication of the Final Report of the Pharmaceutical Sectoral Inquiry
France: New Cost-Containment Measures Proposed for 2010; Continued Steady Growth in the Generics Market
Germany: Market Trends; Pressure for Reform from Health Insurance Funds; Expansion of the Second Opinion Process; New Government’s Deliberations on Healthcare Policy
Italy: Creation of a New Working Group on Access to Medicines; Italian Medicines Agency’s New Focus on Pharmaceutical Strategy and Economic Policy
Spain: Double Legal Setback for the Pharmaceutical Industry
United Kingdom: Economic Slowdown Exerts Pressure on Prescribing Budgets; Supply Shortages Resulting from Parallel Exports; Likely Delay to the Introduction of Generics Substitution; Review of NICE’s Infl uence on Pharmaceutical Innovation
Japan: Prospective Trial Introduction of a Price Maintenance System; New Government Likely to Stimulate the Generics Market; Barrier to Reimbursement of Drugs Not Yet Approved in Japan
Outlook and Implications for the Pharmaceutical Industry
Tables: 1. Key Proposals for U.S. Healthcare Reform
Figures: 1. Health Insurance Coverage of the Total U.S. Population, 1999-2008; 2. Health Insurance Coverage of the Nonelderly U.S. Population, 1999-2008; 3. Health Insurance Coverage of the Senior U.S. Population, 1999-2008; 4. Percentage of U.S. Employers Sponsoring Employee Health Benefi ts, 1999-2009; 5. U.S. Employers That Sponsor Employee Health Benefi ts: Likelihood of Implementing Various Cost-Containment Measures in the Next Year; 6. Percentage of U.S. Covered Workers in Formulary Designs of Various Structures, 2000-2009; 7. Average Copayments in the United States by Formulary Tier, 2000-2009; 8. Average Coinsurance Rates in the United States by Formulary Tier, 2000-2009; 9. U.S. Employers’ Use of Common Utilization Management Tools, 2007-2009; 10. U.S. Managed Care Executives’ Priorities for Comparative Effectiveness Research; 11. Generics’ Share of the Japanese Pharmaceutical Market, Fiscal Years 2006-2008

More Germany Pricing Reports

Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure by GBI Research
Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure Summary GBI Research, the leading business intelligence provider, ...

Germany Pharmaceutical Market Overview - New pricing rules set to negatively impact drug sales both domestically and internationally by Datamonitor
Introduction The German prescription pharmaceutical market was valued at $38.3 bn in 2009, with an annual growth rate of 4.4% between 2008 and 2009. However, future ...

Special Report: Pharmaceutical Pricing and Reimbursement in Germany, 2008 by Decision Resources
Over the past two decades, the German pharmaceutical market has undergone a greater number of radical reforms than any other major drug market. With the ...

Pharmaceutical Pricing and Reimbursement in Germany by Decision Resources
Introduction At first glance, the German pharmaceutical market looks extremely attractive to drug manufacturers. However, manufacturers seeking to do business in Germany must contend ...

See all reports like this >>

More Germany Reports

D&B Country RiskLine Report: Germany by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

D&B Country Report: Germany by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...

Germany: Country Profile by MarketLine
INTRODUCTION This report provides a detailed analysis on Germany, providing an overview of its political, economic and business environment, represented both textually and in graph and ...

2007 Germany Industry & Market Outlook report by Barnes Reports
The 2007 Germany Industry & Market Outlook report is the leading annual publication that describes over 100 major industries in Germany and 500+ minor industries ...

The Economic Competitiveness of Germany: Financials Returns, Labor Productivity and International Gaps by Icon Group International, Inc.
Is Germany competitive? With the globalization of markets, the increased mobility of corporate assets, and the need for productive human resources, this question has ...

See all reports like this >>

H4-13, Market Access, Pricing, and Reimbursement News in the Third Quarter of 2009

Share this report

Other tasks

Research Assistance

Related Markets

Pricing Reports

Free Alert Me service